Gaucher Disease

Challenges in Assessment and Management of Bone Disease

CE Satellite Symposium

Program Overview

Program Overview:

Although Gaucher disease (GD) is one of the most widely known of the lysosomal diseases, and treatments are available, there is still so much that needs to be addressed. This satellite session will aim to address the critical gap in diagnosing and managing bone disease in individuals with Gaucher disease, focusing on the challenges and current treatment protocols. Bone disease, though a common and debilitating aspect of GD, often remains underdiagnosed and undertreated, even during enzyme replacement therapy (ERT), due to the focus on other clinical manifestations. The session will raise awareness and promote the need for standardized protocols for monitoring bone involvement, ultimately shifting from a treatment-based approach to a personalized, patient-centered model of care for bone disease in GD.

Gaucher Disease

Challenges in Assessment and Management of Bone Disease

Wednesday, February 5, 2025
12:15- 13:15 PST
Grand Hall AB

Agenda

12:15 Welcome and Introduction Ozlem Goker-Alpan
12:20 Molecular and Cellular Mechanisms of Bone Involvement in Gaucher Disease Greg Grabowski
12:33 Advanced Methods for Quantifying Bone Involvement in GD: From Traditional Imaging to AI Innovations Ravi Kamath
12:46 Comprehensive, Patient-Centered Strategies for Managing Gaucher Disease-Related Bone Disease Patrick Deegan
12:59 Q&A and Discussion Faculty – Moderated by Chair
13:15 Adjourn

Target Audience:

This activity is intended for healthcare professionals involved in the screening, diagnosis, management, and treatment of lysosomal diseases affecting both children and adults, with research and clinically relevant information geared specifically to the following professionals: medical and clinical geneticists; genetic counselors; pediatricians; neurologists; psychologists; nurse practitioners; physician assistants; and patient advocates.

Learning Objectives:

  1. Recognize the significance of bone manifestations as early clinical signs of Gaucher disease during diagnostic evaluation and patient management.
  2. Discuss the impact of treatments on bone disease in GD and the need for ongoing skeletal monitoring.
  3. Integrate recommendations for regular evaluation of bone disease into care of patients with GD, including appropriate diagnostic tests and more uniform interpretation.
  4. Develop shared criteria to request or perform imaging studies for assessment of bone disease in patients with GD to better understand the response to therapies, and the need for review of treatment plans based on more consistent interpretation of results.

Faculty

Ozlem Goker-Alpan, MD (Chair)

Lysosomal and Rare Disorders
Research & Treatment Center, Inc.
Fairfax, VA, United States

Patrick Deegan, MD

Cambridge University Hospitals
NHS Foundation Trust
Cambridge, United Kingdom

Gregory A. Grabowski, MD

Cincinnati Children’s Hospital
Research Foundation
Cincinnati, OH, United States

Ravi Kamath, MD, PhD

Fairfax Radiological Consultants
Inova Health System
Fairfax, VA, United States

CE Accreditation:

This activity is jointly provided by Postgraduate Institute for Medicine and Saterdalen & Associates, LLC.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Saterdalen & Associates, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

Faculty Disclosure & Information:

Grant Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals, U.S.A., Inc.

Evaluation Instructions:

CE Credit and Certificates

Click here: CME University

Username: Your Email
New User Password: WORLD!
Course Code: 18689

Download Instructions (PDF)

Step 1

Register or Login

Please go online to CME University at: cmeuniversity.com, and register or login.

New users will need to Register (click on “Create New Account”).

  • Your Username is your email address
  • New Users – use the Password WORLD! (write this down)

Previous Users can login.

  • If you have forgotten your password, click on “Forgot my password” and enter your email address to reset your password.

Step 2

Complete Evaluation

Once logged in, follow these steps:

  1. Click on the “Find Post-Test/Evaluation by Course:” at the top of the page.
  2. Type in “18689” and hit enter.
  3. Click on the activity title when it appears.
  4. Choose your profession/type of credit you are seeking (AMA, ANCC, or Certificate of Attendance).
  5. Complete the online Evaluation Form.

Upon completion of each online Evaluation form, you will have immediate access to a certificate to print or save for your files.

If you have any questions regarding the certification for these activities, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.